on MEDINCELL (EPA:MEDCL)
Medincell and Teva Present Phase 3 Olanzapine LAI Data
Medincell, partnered with Teva, announced the presentation of data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting. The event takes place from September 17-21 in San Diego. Following the presentation, Teva will host a conference call on September 22 to discuss these findings with analysts and investors.
Olanzapine LAI, known as mdc-TJK or TEV-‘749, is an investigational drug designed for monthly subcutaneous administration. It aims to treat schizophrenia, utilizing Medincell’s co-polymer technology (SteadyTeq™) for controlled drug release. Teva plans to submit a New Drug Application (NDA) for this medication in Q4 2025, marking a crucial step towards regulatory approval.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDINCELL news